Rationale: Patients with invasive mechanical ventilation (IMV) frequently develop diaphragm dysfunction and experience difficult weaning. Recent ex vivo work suggests that a subset of mechanically ventilated ICU patients may exhibit diaphragm hibernation, an energy conserving myosin state that reduces force generation and may lead to a reversible increase in diaphragm strength over time. However, it is unknown whether diaphragm hibernation can be demonstrated in vivo during IMV and which clinical and biological factors are associated with this phenotype. Objective: Primary objective is to determine the driving factors (biomarkers) of diaphragm hibernation during IMV. Secondary objectives are to determine the proportion of ventilated critically ill patients who exhibit diaphragm hibernation during IMV, to investigate inflammatory and metabolic factors and other clinical exposures associated with diaphragm hibernation, and to explore associations between diaphragm hibernation and weaning related and survival outcomes. Study design: Prospective, observational, longitudinal cohort study. Study population: Adult ICU patients receiving IMV, expected to remain mechanically ventilated for at least 72 hours. Intervention (if applicable): Not applicable. This is an observational study. Study specific procedures consist of repeated phrenic nerve magnetic stimulation and additional blood sampling. Main study parameters/endpoints: The primary study parameter is the proportion of participants exhibiting diaphragm hibernation during IMV. Diaphragm hibernation is defined as an increase in stimulated twitch tracheal pressure (Ptr,stim), a measure of diaphragm strength, of at least 10% relative to baseline (Day 0-1) at any follow up assessment (Day 2, 3, 5, or 7) obtained before extubation or death. Ptr,stim will be assessed repeatedly on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participant burden is limited and mainly consists of repeated phrenic nerve magnetic stimulation during a ventilator delivered end expiratory occlusion and additional blood sampling of 9.5 mL per time point, up to a total of 47.5 mL across the study period. Magnetic stimulation is non-invasive and expected discomfort is transient. Rare transient physiological changes may occur and measurements are performed under continuous ICU monitoring and will be postponed or omitted if considered unsafe or interfering with clinical care. Direct benefit for participants is limited, but the study may provide clinically relevant knowledge on diaphragm hibernation and its driving factors. The research questions are specific to diaphragm physiology during IMV in critically ill patients, therefore the study is group related and cannot be performed in a different population.
Study Type
OBSERVATIONAL
Enrollment
112
Radboud University Medical Center (Radboudumc)
Nijmegen, Gelderland, Netherlands
Blood C reactive protein level
C reactive protein will be assessed by blood sample.
Time frame: C reactive protein will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Blood procalcitonin level
Procalcitonin will be assessed by blood sample.
Time frame: Procalcitonin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Blood metabolic biomarkers level
Metabolic biomarkers will be assessed by blood sample using OLINK Target 96 panel.
Time frame: Metabolic biomarkers will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Blood TNF-α level
TNF-α will be assessed by blood sample.
Time frame: TNF-α will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Blood IL-10 level
IL-10 will be assessed by blood sample.
Time frame: IL-10 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Blood IL-8 level
IL-8 will be assessed by blood sample.
Time frame: IL-8 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Blood IL-6 level
IL-6 will be assessed by blood sample.
Time frame: IL-6 will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Blood ferritin level
Ferritin will be assessed by blood sample.
Time frame: Ferritin will be assessed on Day 0-1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Proportion of participants exhibiting diaphragm hibernation during invasive mechanical ventilation
Diaphragm hibernation is defined as an increase in stimulated twitch tracheal pressure (Ptr,stim), a measure of diaphragm strength, of at least 10% relative to baseline (Day 0 to 1) at any follow up assessment (Day 2, 3, 5, or 7) obtained before extubation or death.
Time frame: Ptr,stim will be assessed repeatedly on Day 0 to 1, Day 2, Day 3, Day 5, and Day 7, or until extubation or death, whichever occurs first.
Number of days from intubation to successful extubation
Data about number of days from intubation to successful extubation will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
Number of days from first SBT to successful extubation
Data about number of days from first SBT to successful extubation will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
Incidence of weaning failure
Weaning failure is defined as SBT failure or reintubation within 48 hours. Data will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or ICU/hospital discharge or death, whichever occurs first
ICU length of stay
Data about ICU length of stay will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
Hospital length of stay
Data about hospital length of stay will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
ICU mortality
Data about ICU mortality will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
Hospital mortality
Data about hospital mortality will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first
Day 28 all-cause mortality
Data about day 28 all-cause mortality will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28 or death, whichever occurs first
ICU-free days through day 28
Data about ICU-free days through day 28 will be retrieved from electronic medical records.
Time frame: Collected from ICU discharge until Day 28 or death, whichever occurs first
Hospital-free days through day 28
Data about hospital-free days through day 28 will be retrieved from electronic medical records.
Time frame: Collected from hospital discharge until Day 28 or death, whichever occurs first
Time to ICU discharge alive through day 28
Data about time to ICU discharge alive through day 28 will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or ICU discharge or death, whichever occurs first
Time to hospital discharge alive through day 28
Data about time to hospital discharge alive through day 28 will be retrieved from electronic medical records.
Time frame: Collected from study inclusion until Day 28, or hospital discharge or death, whichever occurs first